drugset / Trial / NCT00603993

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

NCT00603993

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label study.

Timeline

Start
2006-03
Primary completion
2006-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Adalimumab Monoclonal antibody 80 mg Subcutaneous

Indications